ALLO
insider transactionsAllogene Therapeutics, Inc. — buys & sells by directors, officers and 10% owners A shareholder owning more than 10% of the company. Must report trades, but usually a weaker signal than an officer or director. (SEC Form 4).
Net shares · 365d
-288.0K
0 buy · 288.0K sell
Net value · 365d
-$556.2K
$0 in · $556.2K out
Sentiment · 365d
Net selling
0% buying · 100% selling
Open-market trades · 365d
12
0 buy · 288.0K sell
Net buy / sell volume
Not enough data to chart yet.
Tap or hover the chart for daily net volume. Green = net buying, red = net selling.
All transactions
-
Sell·S
SVP, Finance
$22.1K
9.6K sh · $2.31
Own -7%
-
Sell·S
SVP, Chief Technical Officer
$7.2K
2.9K sh · $2.50
Own -1%
-
Sell·S
SVP, Chief Technical Officer
$11.9K
4.8K sh · $2.47
Own -2%
-
Sell·S
David D Chang KEY
President and CEO
$118.0K
47.8K sh · $2.47
Own -1%
-
Sell·S
SVP, Chief Technical Officer
$18.5K
7.1K sh · $2.60
Own -3%
-
Grant·A
SVP, Chief Technical Officer
$0
105.7K sh
Own New
-
Grant·A
SVP, Chief Technical Officer
$0
373.8K sh
Own New
-
Sell·S
SVP, Chief Technical Officer
$13.1K
7.5K sh · $1.73
Own -3%
-
Grant·A
David D Chang KEY
President and CEO
$0
392.6K sh
Own New
-
Grant·A
David D Chang KEY
President and CEO
$0
1.4M sh
Own New
-
Sell·S
David D Chang KEY
President and CEO
$171.5K
95.3K sh · $1.80
Own -2%
-
Grant·A
CHIEF FINANCIAL OFFICER
$0
152.5K sh
Own New
-
Grant·A
CHIEF FINANCIAL OFFICER
$0
539.1K sh
Own New
-
Sell·S
CHIEF FINANCIAL OFFICER
$42.2K
24.0K sh · $1.76
Own -2%
-
Grant·A
SVP, Finance
$0
50.8K sh
Own New
-
Grant·A
SVP, Finance
$0
179.7K sh
Own New
-
Sell·S
SVP, Finance
$7.2K
4.2K sh · $1.72
Own -3%
-
Grant·A
EVP of R&D
$0
203.3K sh
Own New
-
Grant·A
EVP of R&D
$0
718.8K sh
Own New
-
Sell·S
EVP of R&D
$63.2K
35.7K sh · $1.77
Own -6%
-
Grant·A
SVP, General Counsel
$0
152.5K sh
Own New
-
Grant·A
SVP, General Counsel
$0
539.1K sh
Own New
-
Sell·S
SVP, General Counsel
$40.3K
22.9K sh · $1.76
Own -4%
-
Grant·A
Director
$0
263.0K sh
Own New
-
Grant·A
Director
$0
929.9K sh
Own New
-
Sell·S
EVP of R&D
$41.0K
26.3K sh · $1.56
Own -4%
| Date▾ | Insider | Type | Shares | Value |
|---|---|---|---|---|
| Apr 21, 2026 | Annie Yoshiyama | Sell S | 9.6K | $22.1K |
| Mar 31, 2026 | Benjamin Machinas Beneski | Sell S | 2.9K | $7.2K |
| Mar 16, 2026 | Benjamin Machinas Beneski | Sell S | 4.8K | $11.9K |
| Mar 16, 2026 | David D Chang KEY | Sell S | 47.8K | $118.0K |
| Mar 2, 2026 | Benjamin Machinas Beneski | Sell S | 7.1K | $18.5K |
| Feb 2, 2026 | Benjamin Machinas Beneski | Grant A | 105.7K | $0 |
| Feb 2, 2026 | Benjamin Machinas Beneski | Grant A | 373.8K | $0 |
| Feb 2, 2026 | Benjamin Machinas Beneski | Sell S | 7.5K | $13.1K |
| Feb 2, 2026 | David D Chang KEY | Grant A | 392.6K | $0 |
| Feb 2, 2026 | David D Chang KEY | Grant A | 1.4M | $0 |
| Feb 2, 2026 | David D Chang KEY | Sell S | 95.3K | $171.5K |
| Feb 2, 2026 | Geoffrey M. Parker KEY | Grant A | 152.5K | $0 |
| Feb 2, 2026 | Geoffrey M. Parker KEY | Grant A | 539.1K | $0 |
| Feb 2, 2026 | Geoffrey M. Parker KEY | Sell S | 24.0K | $42.2K |
| Feb 2, 2026 | Annie Yoshiyama | Grant A | 50.8K | $0 |
| Feb 2, 2026 | Annie Yoshiyama | Grant A | 179.7K | $0 |
| Feb 2, 2026 | Annie Yoshiyama | Sell S | 4.2K | $7.2K |
| Feb 2, 2026 | Zachary Roberts | Grant A | 203.3K | $0 |
| Feb 2, 2026 | Zachary Roberts | Grant A | 718.8K | $0 |
| Feb 2, 2026 | Zachary Roberts | Sell S | 35.7K | $63.2K |
| Feb 2, 2026 | Earl Martin Douglas | Grant A | 152.5K | $0 |
| Feb 2, 2026 | Earl Martin Douglas | Grant A | 539.1K | $0 |
| Feb 2, 2026 | Earl Martin Douglas | Sell S | 22.9K | $40.3K |
| Feb 2, 2026 | Arie Belldegrun | Grant A | 263.0K | $0 |
| Feb 2, 2026 | Arie Belldegrun | Grant A | 929.9K | $0 |
| Jan 21, 2026 | Zachary Roberts | Sell S | 26.3K | $41.0K |
About ALLO insider trading
This page tracks insider transactions for Allogene Therapeutics, Inc. (ALLO) reported to the U.S. Securities and Exchange Commission on Form 4. Corporate insiders — directors, executive officers and beneficial owners of more than 10% of the stock — must disclose their trades within two business days. Open-market purchases (code P) and sales (code S) made at the insider's discretion are the most-watched opportunistic signals, while awards (A), option exercises (M) and tax-withholding (F) reflect compensation rather than conviction. Trades marked 10b5-1 were made under a pre-arranged plan and are considered routine. A cluster buy — several insiders buying within a short window — is historically a stronger bullish indicator than any single trade.